BioSpace News Archive

joimax ® is continuing its year-over-year double digit growth. Over the past 9 months, joimax ® has grown more than 25% globally and in the United States alone, more than 35%.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster presentations, namely the Phase 2 AURELIO-04study design of the IL-15 superagonist, SOT101as a Trial in Progress and nonclinical data on mechanism of action of its BOXR T cell platform at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that the U.S. Food and Drug Administration, cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT3789, a first-in-class potent and selective SMARCA2 protein degrader.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its third quarter 2022 financial results on Monday, October 31, 2022, after the market closes.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced today the granting of a patent by the U.S. Patent and Trademark Office.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”) today announced the publication of abstracts for two posters that will be presented at the upcoming 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (“2022 ENA”), taking place from October 26th to October 28th, 2022 in Barcelona, Spain.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced today the company will present new data and research at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, being held October 21-26 in Charlotte, NC.

Medtronic plc, the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system.

Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced a comprehensive manufacturing collaboration utilizing Charles River’s extensive contract development and manufacturing services in both plasmid DNA and viral vectors.

Juno Diagnostics, a company focused on bringing vital health information to patients by improving access, affordability and transparency, announced the addition of Gina Grayum to its commercial leadership team.